Shares of Kura Oncology (NASDAQ:KURA) gained in the premarket on Thursday after the company, with its Japanese partner Kyowa Kirin (OTCPK:KYKOF) (OTCPK:KYKOY), updated early-stage trial data for ...

Kura will lead commercialization in the U.S. while Kyowa Kirin has commercialization rights in the rest of the world. Kura is in line for up to $1.2 billion in milestone payments.

Kura Oncology has signed a global partnership with the Japanese drugmaker Kyowa Kirin to develop and sell Kura’s experimental treatment for acute leukemia, the companies said Wednesday. Kyowa is ...

Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin have announced that full data from the pivotal KOMET-001 trial of their investigational menin inhibitor, ziftomenib, will be presented at the 2025 ...